| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Department of Oncology/Pathology, Division of Cellular and Molecular Tumor Pathology, Karolinska Hospital, SE-171 76 Stockholm, Sweden [L. G., A. G., B. B., Y. X., G. N., A. D., J. W., A. B., O. L.]; Department of Biotechnology, Royal Institute of Technology, SE-100 44 Stockholm, Sweden [J. L.]; and Microbiology and Tumor Biology Center, Karolinska Institute, SE-171 77 Stockholm, Sweden [K. G. W.]
We investigated the functional impact of p53 on insulin-like growth factor I receptor (IGF-IR) expression in malignant cells. Using the BL-41tsp53-2 cell line, a transfectant carrying temperature-sensitive (ts) p53 and endogenous mutant p53 (codon 248), we demonstrated a drastic down-regulation of plasma membrane-bound IGF-IRs on induction of wild-type p53. However, a similar response was obtained by treatment of BL-41tsp53-2 cells expressing mutant ts p53 with a p53 antisense oligonucleotide. Thus, even if the negative effect of wild-type p53 predominates under a competitive condition, these data indicate that mutant p53 may be important for up-regulation of IGF-IR. To further elucidate this issue, three melanoma cell lines (BE, SK-MEL-5, and SK-MEL-28) that overexpressed p53 were investigated. The BE cell line has a "hot spot" mutation (codon 248) and expresses only codon 248-mutant p53. SK-MEL-28 has a point mutation at codon 145. SK-MEL-5 cells did not exhibit any p53 mutations, but the absence of p21Waf1 expression suggested functionally aberrant p53. Our data suggest that interaction with Mdm-2 may underlie p53 inactivation in these cells. Using p53 antisense oligonucleotides, we demonstrated a substantial down-regulation of cell surface expression of IGF-IR proteins in all melanoma cell lines after 24 h. This was paralleled by decreased tyrosine phosphorylation of IGF-IR and growth arrest, and, subsequently, massive cell death was observed (this was also seen in BL-41tsp53-2 cells with mutant conformation of ts p53). Taken together, our results suggest that up-regulation of IGF-IR as a result of expression of aberrant p53 may be important for the growth and survival of malignant cells.
This article has been cited by other articles:
|
|
 |
|
  N. P. Agaram, M. P. Laquaglia, B. Ustun, T. Guo, G. C. Wong, N. D. Socci, R. G. Maki, R. P. DeMatteo, P. Besmer, and C. R. Antonescu Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors Clin. Cancer Res., May 15, 2008; 14(10): 3204 - 3215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Vasilcanu, D. Vasilcanu, B. Sehat, S. Yin, A. Girnita, M. Axelson, and L. Girnita Insulin-Like Growth Factor Type-I Receptor-Dependent Phosphorylation of Extracellular Signal-Regulated Kinase 1/2 but not Akt (Protein Kinase B) Can Be Induced by Picropodophyllin Mol. Pharmacol., March 1, 2008; 73(3): 930 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Girnita, S. K. Shenoy, B. Sehat, R. Vasilcanu, D. Vasilcanu, A. Girnita, R. J. Lefkowitz, and O. Larsson beta-Arrestin and Mdm2 Mediate IGF-1 Receptor-stimulated ERK Activation and Cell Cycle Progression J. Biol. Chem., April 13, 2007; 282(15): 11329 - 11338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Douglas, A. G. Gianoukakis, S. Kamat, and T. J. Smith Aberrant Expression of the Insulin-Like Growth Factor-1 Receptor by T Cells from Patients with Graves' Disease May Carry Functional Consequences for Disease Pathogenesis J. Immunol., March 1, 2007; 178(5): 3281 - 3287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Monte, M. Simonatto, L. Y. Peche, D. R. Bublik, S. Gobessi, M. A. Pierotti, M. Rodolfo, and C. Schneider MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents PNAS, July 25, 2006; 103(30): 11160 - 11165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang and G. Li ING3 Promotes UV-induced Apoptosis via Fas/Caspase-8 Pathway in Melanoma Cells J. Biol. Chem., April 28, 2006; 281(17): 11887 - 11893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Girnita, C. All-Ericsson, M. A. Economou, K. Astrom, M. Axelson, S. Seregard, O. Larsson, and L. Girnita The Insulin-Like Growth Factor-I Receptor Inhibitor Picropodophyllin Causes Tumor Regression and Attenuates Mechanisms Involved in Invasion of Uveal Melanoma Cells Clin. Cancer Res., February 15, 2006; 12(4): 1383 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Economou, C. All-Ericsson, V. Bykov, L. Girnita, A. Bartolazzi, O. Larsson, and S. Seregard Receptors for the Liver Synthesized Growth Factors IGF-1 and HGF/SF in Uveal Melanoma: Intercorrelation and Prognostic Implications Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4372 - 4375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Girnita, S. K. Shenoy, B. Sehat, R. Vasilcanu, A. Girnita, R. J. Lefkowitz, and O. Larsson {beta}-Arrestin Is Crucial for Ubiquitination and Down-regulation of the Insulin-like Growth Factor-1 Receptor by Acting as Adaptor for the MDM2 E3 Ligase J. Biol. Chem., July 1, 2005; 280(26): 24412 - 24419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. All-Ericsson, L. Girnita, A. Muller-Brunotte, B. Brodin, S. Seregard, A. Ostman, and O. Larsson c-Kit-Dependent Growth of Uveal Melanoma Cells: A Potential Therapeutic Target? Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2075 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Ferguson, E. Kurowska, D. J. Freeman, A. F. Chambers, and D. J. Koropatnick A Flavonoid Fraction from Cranberry Extract Inhibits Proliferation of Human Tumor Cell Lines J. Nutr., June 1, 2004; 134(6): 1529 - 1535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Girnita, L. Girnita, F. d. Prete, A. Bartolazzi, O. Larsson, and M. Axelson Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth Cancer Res., January 1, 2004; 64(1): 236 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Edmondson, S. P. Thumiger, G. A. Werther, and C. J. Wraight Epidermal Homeostasis: The Role of the Growth Hormone and Insulin-Like Growth Factor Systems Endocr. Rev., December 1, 2003; 24(6): 737 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Girnita, A. Girnita, and O. Larsson Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor PNAS, July 8, 2003; 100(14): 8247 - 8252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Idelman, T. Glaser, C. T. Roberts Jr., and H. Werner WT1-p53 Interactions in Insulin-like Growth Factor-I Receptor Gene Regulation J. Biol. Chem., January 24, 2003; 278(5): 3474 - 3482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Decraene, P. Agostinis, R. Bouillon, H. Degreef, and M. Garmyn Insulin-like Growth Factor-1-mediated AKT Activation Postpones the Onset of Ultraviolet B-induced Apoptosis, Providing More Time for Cyclobutane Thymine Dimer Removal in Primary Human Keratinocytes J. Biol. Chem., August 30, 2002; 277(36): 32587 - 32595. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
